URGN · Insider Trading
UroGen Pharma Ltd. Ordinary Shares
Every open-market purchase and sale reported by URGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Chris Degnan | Chief Financial Officer | MIXED | +2,281 | −$80.79K |
| 2026-09-09 | Mark Schoenberg | Chief Medical Officer | MIXED | +796 | −$37.38K |
| 2026-09-09 | Jason Drew Smith | General Counsel | MIXED | +1,815 | −$64.62K |
| 2026-08-28 | James A. Robinson Jr. | Director | M | +2,000 | — |
| 2026-08-24 | Mark Schoenberg | Chief Medical Officer | Sell | −60,677 | −$2.85M |
| 2026-07-10 | Mark Schoenberg | Chief Medical Officer | Sell | −10,000 | −$400.00K |
| 2026-06-24 | Leana Wen | Director | A | +18,000 deriv. | — |
| 2026-06-24 | Mark Schoenberg | Chief Medical Officer | Sell | −10,000 | −$350.10K |
| 2026-06-24 | Cynthia M Butitta | Director | A | +18,000 deriv. | — |
| 2026-06-24 | Arie Belldegrun | Director | A | +20,000 deriv. | — |
| 2026-06-24 | James A. Robinson Jr. | Director | A | +18,000 deriv. | — |
| 2026-06-24 | Stuart Holden | Director | A | +20,000 deriv. | — |
| 2026-06-24 | Daniel George Wildman | Director | A | +18,000 deriv. | — |
| 2026-06-09 | Mark Schoenberg | Chief Medical Officer | MIXED | +4,778 | −$142.56K |
| 2026-05-27 | James A. Robinson Jr. | Director | M | +2,000 | — |
| 2026-05-11 | Mark Schoenberg | Chief Medical Officer | Sell | −10,000 | −$300.00K |
| 2026-02-27 | James A. Robinson Jr. | Director | M | +2,000 | — |
| 2026-02-19 | Elizabeth A. Barrett | Chief Executive Officer | A | +153,195 deriv. | — |
| 2026-02-11 | Jason Drew Smith | General Counsel | MIXED | +8,021 | −$147.26K |
| 2026-02-04 | Mark Schoenberg | Chief Medical Officer | Sell | −7,373 | −$145.17K |
| 2026-02-03 | Chris Degnan | Chief Financial Officer | A | +32,609 deriv. | — |
| 2026-02-03 | Mark Schoenberg | Chief Medical Officer | M | +13,333 | — |
| 2025-12-01 | Cynthia M Butitta | Director | M | +2,000 | — |
| 2025-12-01 | Daniel George Wildman | Director | M | +2,000 | — |
| 2025-12-01 | James A. Robinson Jr. | Director | M | +2,000 | — |
| 2025-12-01 | Leana Wen | Director | M | +2,000 | — |
| 2025-12-01 | Stuart Holden | Director | M | +2,000 | — |
| 2025-11-20 | Mark Schoenberg | Chief Medical Officer | Sell | −10,000 | −$250.00K |
| 2025-10-09 | Chris Degnan | Chief Financial Officer | MIXED | +2,280 | −$37.12K |
| 2025-09-09 | Jason Drew Smith | General Counsel | MIXED | +1,813 | −$29.05K |
| 2025-09-09 | Mark Schoenberg | Chief Medical Officer | MIXED | +796 | −$16.64K |
| 2025-08-27 | Leana Wen | Director | A | +18,000 deriv. | — |
| 2025-08-27 | Daniel George Wildman | Director | A | +18,000 deriv. | — |
| 2025-08-27 | Stuart Holden | Director | A | +18,000 deriv. | — |
| 2025-08-27 | Cynthia M Butitta | Director | A | +18,000 deriv. | — |
| 2025-08-27 | James A. Robinson Jr. | Director | A | +18,000 deriv. | — |
| 2025-08-27 | Arie Belldegrun | Director | A | +20,000 deriv. | — |
| 2025-08-13 | Mark Schoenberg | Chief Medical Officer | Sell | −10,000 | −$176.90K |
| 2025-07-30 | Elizabeth A. Barrett | Chief Executive Officer | A | +87,615 deriv. | — |
| 2025-07-30 | Mark Schoenberg | Chief Medical Officer | MIXED | +4,851 | −$98.55K |
| 2025-07-30 | Jason Drew Smith | General Counsel | MIXED | +8,978 | −$143.97K |
| 2025-06-11 | Mark Schoenberg | Chief Medical Officer | MIXED | +4,838 | −$38.04K |
| 2025-02-04 | Elizabeth A. Barrett | Chief Executive Officer | A | +96,377 deriv. | — |
| 2025-02-04 | Jason Drew Smith | General Counsel | MIXED | +7,288 | −$82.20K |
| 2025-02-04 | Mark Schoenberg | Chief Medical Officer | MIXED | +3,449 | −$50.70K |
| 2024-10-09 | Chris Degnan | Chief Financial Officer | A | +87,592 deriv. | — |
| 2024-09-12 | Dong Kim | Chief Financial Officer | M | +2,500 | — |
| 2024-09-12 | Jason Drew Smith | General Counsel | MIXED | +1,812 | −$19.89K |
| 2024-09-12 | Mark Schoenberg | Chief Medical Officer | MIXED | +807 | −$11.24K |
| 2024-08-08 | Leana Wen | Director | A | +10,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Arie Belldegrun | Director | 408,693 | $13.91M |
| Elizabeth A. Barrett | Chief Executive Officer | 326,691 | $11.12M |
| Mark Schoenberg | Chief Medical Officer | 67,849 | $2.31M |
| Jason Drew Smith | General Counsel | 54,660 | $1.86M |
| James A. Robinson Jr. | Director | 8,000 | $272.32K |
| Chris Degnan | Chief Financial Officer | 6,763 | $230.21K |
| Cynthia M Butitta | Director | 2,000 | $68.08K |
| Stuart Holden | Director | 2,000 | $68.08K |
| Leana Wen | Director | 2,000 | $68.08K |
| Daniel George Wildman | Director | 2,000 | $68.08K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the URGN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.